PATENT CLAIM ANALYSIS

Application Number: 16282120
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-07
Patent Classification: ["424", "145100"]

Abstract:
Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.

Claim (Index 18):
An injectable formulation, comprising:\n a polysorbate; a diluent; and a human antibody or antigen-binding fragment thereof that specifically binds human nerve growth factor (NGF), wherein the antibody comprises the three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) contained within any one of the HCVR sequences selected from the group consisting of SEQ ID NOs: 100 and 108; and the three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within any one of the LCVR sequences selected from the group consisting of SEQ ID NOs: 92, 102 and 110.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 99.0
- Lexical Diversity: 1.225
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14038349', '13648477', '12888751', '15144574', '12188330']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7840705769346236
- 35 USC 102 Novelty (BERT): 0.6195752711601049
- Combined Prediction Score: 0.7676210463571718
- Mean Citation Score: 529.2572640000002
- Max Citation Score: 573.95435
- Similarity Product: 512.5693934956163

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test